Life Sciences Drug DevelopmentCambridge, MA
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new and more efficient treatment for cancer patients.
NanoXray products are amplifying current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors.
Nanobiotix’s lead product NBTXR3 is currently under clinical development in EU, US, and Asia for soft tissue sarcoma, head and neck cancer, prostate cancer, rectal cancer and liver cancers (HCC and liver metastases) The Company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia and has filed in August 2016 for market approval in Europe for its lead product NBTXR3
Nanobiotix is listed on the regulated market of Euronext in Paris since 2012. The Company Headquarter is based in Paris, France. The US Affiliate is based in Cambridge, Massachusetts